Recent advances in inflammatory skin diseases

Scottish Medical Journal

Volumn 53, Issue 2, 2008, Pages 30-34

  Thind, C K ^a   Ormerod, A D ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADALIMUMAB; ALEFACEPT; ANTIBIOTIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA DEFENSIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; ETRETINATE; FOLIC ACID; HEPATITIS B VACCINE; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; METHYLDOPA; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIMECROLIMUS; PREDNISOLONE; RIBOMUNYL; STEROID; TACROLIMUS; TETRACYCLINE DERIVATIVE; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACNE; ATOPIC DERMATITIS; AUTOIMMUNITY; BULLOUS PEMPHIGOID; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; GENE LOCUS; HEPATITIS B; HEPATITIS C; HUMAN; LICHEN PLANUS; LICHENOID; LIVER FIBROSIS; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EDUCATION; NONHUMAN; PATHOGENESIS; PHARMACOGENOMICS; PHOTOTHERAPY; PREVALENCE; PROFESSIONAL KNOWLEDGE; PSORIASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INFLAMMATION; CHRONIC DISEASE; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; INFLAMMATION; SKIN DISEASE;

CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATION; SKIN DISEASES;

EID: 47549104087     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1258/rsmsmj.53.2.30     Document Type: Review

References (45)

1. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based Study. Arch Dermatol 2005; 141: 1537-41.
2. Elder JT. PSORS1: linking genetics and immunology. J Invest Dermatol 2006; 126: 1205-6.
3. Boyman O, Hefti HP, Conrad C,. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumour necrosis factor-alpha. J Exp Med 2004; 199: 731-6.
4. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
5. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12.
6. Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-8.
7. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
8. Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther 2006; 8: 111.
9. Dixon WG, Watson K, Lunt M, et al. British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Arthritis Rheum 2006; 54: 2368-76.
10. Camp RDR, El-Rachkidy RG, Young HS, et al. Immunological evidence for increased reactivity to secreted Streptococcus pyogenes proteins in chronic plaque psoriasis:FC-13. Br J Dermatol, Supplement 2006; 154(supplement 1): 5.
11. Diluvio L, Vollmer S, Besgen P, et al. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006; 176: 7104-11.
12. Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine and purine metabolism predict clinical response to methotrexate therapy in psoriasis. Br J Dermatol 2006; 155: 255.
13. Chalmers RJ, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005; 152: 444-50.
14. Mallbris L, Granath F, Hamstenn A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-21.
15. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
16. Prodanovich S, Ma F, Taylor R,. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-7.
17. Chakravarty K, McDonald H, Pullar T et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for disease-modifying anti-rheumatic drug therapy (DMARD) in consultation with the British Association of Dermatologists behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group in association with the British Association of Dermatologists (BAD). Rheumatology 2006; epub: doi:10.1093/rheumatology/kel216a
18. Hoffjan S, Epplen JT. The genetics of atopic dermatitis: recent findings and future options. J Mol Med 2005; 83: 682-92.
19. Segre JA. Epidermal barrier formation and recovery in skin disorders. J. Clin Invest 2006; 116:1150-58.
20. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of -function variants of the epidermal barrier protein fillagrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
21. Irvine AD, Mclean WH. Breaking the (un)sound barrier: Filaggrin is a major gene for atopic dermatitis. J Invest Dermatol 2006; 126: 1200-2.
22. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-60.
23. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006; 144: 1-9.
24. Brunetti L, Francavilla R, Tesse R. Effects of oral bacterial immunotherapy in children with atopic eczema/dermatitis syndrome - a pilot study. Biodrugs 2005; 19: 393-99
25. Williams HC. Twice-weekly topical corticosteroid therapy may reduce atopic dermatitis relapses. Arch Dermatol 2004; 140: 1151-2.
26. Hoare C, Li Wan Po A, Williams HC. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4(37): 1-191.
27. Ormerod A D. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause of concern? Br J Dermatol 2005; 153: 701-5.
28. Paus R, Schmelz M, Bíró T, et al. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006; 116: 1174-85.
29. Wang H, Diepgen TL. Atopic dermatitis and cancer risk. Br J Dermatol 2006; 154: 205-10.
30. Margolis DJ, Bowe WP, Hoffstad O, et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005; 141: 1132-6.
31. Velicer CM, Heckbert SR, Lampe JW, et al. Antibiotic use in relation to the risk of breast cancer. JAMA 2004; 291: 827-35.
32. Knekt P, Adlercreutz H, Rissanen H, et al. Does antibacterial treatment for urinary tract infection contribute to the risk of breast cancer? Br J Cancer. 2000; 82:1107-1110.
33. Friedman GD, Oestreicher N, Chan J, et al. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev 2006; 15: 2102-6.
34. Bremner JD, Fani N, Ashraf A et al. Functional brain imaging alterations in acne patients treated with isotretinoin. Am J Psychiatry 2005; 162: 983-91.
35. Nagao Y, Sata M. Hepatitis C virus and lichen planus. J Gastroenterol Hepatol 2004; 19: 1101-13.
36. Lodi G, Giuliani M, Majorana A et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004; 151: 1172-81.
37. Carrozzo M, Francia Di Celle P, Gandolfo S, et al. Increased frequency of HLA-DR6 allele in Italian patients with hepatitis C virus associated oral lichen planus. Br J Dermatol 2001;144: 803-8.
38. Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26: 585-9.
39. Gudi VS, White MI, Cruickshank N et al. Annual incidence and mortality of bullous pemphigoid in the Grampian region of North-East Scotland. Br J Dermatol 2005; 153: 424-7.
40. Rzany B, Partscht K, Jung M et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002; 138: 903-8.
41. Joly P, Benichou J, lok C et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141: 691-8.
42. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J. Clin. Invest. 2006; 116: 1159-66.
43. Joly P, Roujeau JC, Benichou J et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Eng J Med 2002; 346: 321-7.
44. Khumalo N, Kirtschig G, Middleton P, et al. Interventions for bullous pemphigoid. Cochrane database Syst Rev 2006;July 20(3) CD002292.
45. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-8.